Tumor targeting using anti-her2 immunoliposomes
- 1 July 2001
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 74 (1-3) , 95-113
- https://doi.org/10.1016/s0168-3659(01)00315-7
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Biological Effects of Anti-ErbB2 Single Chain Antibodies Selected for Internalizing FunctionBiochemical and Biophysical Research Communications, 2001
- NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancerThe EMBO Journal, 2000
- Selection of Potentially Metastatic Subpopulations Expressing c-erbB-2 from Breast Cancer Tissue by Use of an Extravasation ModelThe American Journal of Pathology, 1998
- Cationic Liposomes Coated with Polyethylene Glycol As Carriers for OligonucleotidesJournal of Biological Chemistry, 1998
- Sterically Stabilized Anti-HER2 Immunoliposomes: Design and Targeting to Human Breast Cancer Cells in VitroBiochemistry, 1997
- Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding SiteJournal of Molecular Biology, 1996
- Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's SarcomaThe Journal of Clinical Pharmacology, 1996
- Stability of HER-2/neu Expression Over Time and at Multiple Metastatic SitesJNCI Journal of the National Cancer Institute, 1993
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987